Self made Metastatic Disease: Challenges to treatment

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/20

encourage image

There's no tags or description

Looks like no tags are added yet.

21 Terms

1
New cards

Learning objectives

  1. Explain the reason metastatic disease is so deadly. List the reasons why metastases are more difficult to treat

  2. Understand what causes tumor heterogeneity and why it makes treating cancer so difficult

  3. Define DTCs and explain why they pose challenges to cancer treatment

  4. Summarize the ways cancer can evolve therapeutic resistance

  5. Explain why the concepts above also hinder our ability to research cancer and develop new effective strategies


2
New cards

Why is cancer so difficult to treat

  • Detection is difficult

  • Treatments are toxic: difficult to kill cancer cells without killing normal cells

    • Cancer pateints are sick and more susceptible to toxic therapies

  • Compliance: patience dont want a treatment with bad side effects

  • Poor drug delivery because

    • Excessive ECM deposition hinders drug diffusion

    • Drug uptake by cancer cells often not efficient

    • Cells get rid of drugs quickly


3
New cards

Why are metastases more deadly than primary tumors?

  • Primary tumors are typically:

    • A single tumor in a single organ (easy to remove/treat)

    • Often in less essential organs (skin, prostate, breast)

    • Easier to detect with routine exams (colonoscopy, mammogram, pap smear)

    • Less aggressive cells (more weaknesses)

    • More responsive to therapies

  • Metastases are typically:

    • Multiple tumors in multiple organs

    • Form in essential highly vascularized organs (lung, liver, brain, bone marrow)

    • Harder and more expensive to detect

    • Metastatic cells are typically more aggressive cells (less weaknesses)

    • Frequently resistant to therapies


4
New cards

Do stromal cells play a role?

  • Stromal cells impact primary tumors and metastasis

  • Either inhibit or promote tumor progression and metastasis

  • Influence the effectiveness of therapies

    • Secrete cytokines, growth factors, and ECM that protect tumor cells from chemotherapy and radiation

    • Influence tumor cell dormancy

    • Secrete ECM that reduces drug delivery

  • Stromal cells can be targeted by treatment

    • Causes side effects/tpxicity (bad)

    • Immune and anti-angiogenic therapies (good)

    • Therapies targeting tumor cells can also kill protumor stromal cells (good) or anti-tumor stromal cells


5
New cards

Brief impact of the immune system on cancer (1 sentence)

the immune system can be both pro and anti cancer and can influence and be influenced by therapies

6
New cards

Targeted therapies (definition, examples of therapies, and downsides)

  • This treatment targets specific molecules required for growth, survival, or spread

    • For example, fusion proteins, mutated or upregulated proteins, pathways activated in cancer cells

  • Examples: Herceptin® (HER2), Vemurafenib (mutant BRAF-V600E), BCR-ABL (Gleevec), EGFR inhibitors, ALK inhibitors, monoclonal antibodies 

  • Negatives

    • Can have adverse side effects

    • Cancer is highly variable with diff driver mutations, so effective targetted therapies will not work for every patient

    • Can be hard to identify patients that will respond (lack adequate biomarkers)

    • Tumor cells evolve resistance

    • Tumor heterogeneity hinders the effectiveness of targeted therapies


7
New cards



What normal processes do cancer cells exploit

  • Self renewal and reduced apoptosis - hallmarks of stem cells

  • intravasation/extravasation - normal processes for leukocytes

  • EMT/invasion/migration: normal during development and tissue repair


8
New cards

3 types of heterogenity within a tumor

  • cancer types differ from each other

    • different driver mutations, strengths, and weaknesses

    • therapies effective for one cancer type may not work for another

  • heterogeneity between cancers of the same type

    • diff combinations of mutations can promote cancer progression

    • a therapy that effectively treats one tumor may not work on another with a different set of mutations

  • heterogeneity within a tumor

    • not all cells in a tumor have the same set of mutations

    • only subsets of cells may be susceptible to a treatment


9
New cards

Linear progression model

  • progression is stepwise and each mutation provides an advantage leading to expansion

  • tumor cells accumulate mutations that make them more agressive

  • metasatic cells often have greater number of mutations


<ul><li><p>progression is stepwise and each mutation provides an advantage leading to expansion</p></li><li><p>tumor cells accumulate mutations that make them more agressive</p></li><li><p>metasatic cells often have greater number of mutations</p></li></ul><p></p>
10
New cards

Independent Clonal Evolution/Progression

  • numerous subpopulations within the tumor progress independently of each other

  • key driver mutations (oncogenes and tumor supressors) rovie a growth advantage → clonal expansion

  • genomic instabiliy causes rapid acumulation of additional mutations

    • Some mutations make cells more aggressive without providing a growth advantage-minimal clonal expansion

    • Multiple metastatic subpopulations with different mutations could exist


<ul><li><p>numerous subpopulations within the tumor progress independently of each other</p></li><li><p>key driver mutations (oncogenes and tumor supressors) rovie a growth advantage → clonal expansion</p></li><li><p>genomic instabiliy causes rapid acumulation of additional mutations</p><ul><li><p>Some mutations make cells more aggressive without providing a growth advantage-minimal clonal expansion</p></li><li><p>Multiple metastatic subpopulations with different mutations could exist</p></li></ul></li></ul><p></p>
11
New cards

Parallel progression model

  • cells desseminate relatively early from the primary tumor mass and evolve independently of cells in the primary tumor


<ul><li><p>cells desseminate relatively early from the primary tumor mass and evolve independently of cells in the primary tumor</p></li></ul><p></p>
12
New cards

How does tumor heterogeneity impact treatment

  • Targeted therapies can only be used if a tumor has the alteration targeted

  • treatments may inhibit/target one subpopulation but not others

  • tumors continue to evolve, resistence

  • metastases have/evolve different alterations (metastases often not biopsied


13
New cards

How does tumor heterogeneity hinder research and drug development

  • Hard to identify causal mutations in a tumor that is very heterogeneous

  • tumor biopsies may miss the imprtant subpopulation

  • tumors have harmless passenger mutations that can look casual

  • most research models do not properly reproduce this heterogeneity


14
New cards

How do tumors become resistant to treatment

  • Advantage of heterogeneity: like antibiotics, treatment can select for existing resistant cells to take over

  • compensation

    • new mutations in the same protein rendering it resistant to the tehrapy

    • mutations in a different protein in the same pathway

    • alterations in anotehr pahway that drives sumular processes

    • increased expression of another protein with simular functions



<ul><li><p>Advantage of heterogeneity: like antibiotics, treatment can select for existing resistant cells to take over</p></li><li><p>compensation</p><ul><li><p>new mutations in the same protein rendering it resistant to the tehrapy</p></li><li><p>mutations in a different protein in the same pathway</p></li><li><p>alterations in anotehr pahway that drives sumular processes</p></li><li><p>increased expression of another protein with simular functions</p></li></ul></li></ul><p></p><p></p>
15
New cards

What are DTCs and what happens after they seed

  • Disseminaed tumor cells (DTCs) are cancer cells that seed a distant organ

  • after seeding, DTCs can

    • die

    • persist as dormant cells

    • micrometastases

    • grow into metastesis

    • outgrow of dormant DTCs and micrometastes causes cancer recurrence from months to decades later


16
New cards

2 theraputic potentials we can learn from DTCs

  • activate processes that cause dormancy

  • inhibit pathways that promote exiting dormancy


17
New cards

how do DTCs evade therapeutic treatment

  • dormant DTCs do not divide so they are resistant to most chemotherapies

  • DTCs that exit dormancy are often resistant to the origonal treatment

  • if outgrowth is triggered by the microenvirpnment, then theres no mutation/alteration within the DTCs to target

  • different mechanisms govern primary vs metastatic growth


18
New cards

Why are therapies that prevent metastatic growth and/or dormancy exit are likely to help the most patients

  • primary tumors can be removed surgically easily

  • patients often already have metaststic disease at diagnosis

  • cancer cells desseminate early

  • preventing the spread of cancer will not help patients with existing DTCs or metastases



19
New cards

Additional challenges to developing effective therapies (4 with details)

  • clinical trials are problematic

    • based on mouse models that dont properly model the complexity of human cancer

    • hard to select appropriate patients (who will respond?)

    • FDA approval is expensive and time consuming

  • Drug development is problematic because drug companiez are buisnesses, and they must make decisions based off profit, not whats best for patients

  • academic research funding is limited

  • traditionally poor collaboration between clinicians, basic scienists, and industry


20
New cards

Emerging technologies that will lead to advances

  • Next Generation Sequencing, massspec, NMR allows omics-based analysis of cancers (genomics, transcriptomics, proteomics, glycomics, metabolomics, Lipidomics)- can reveal new targets and facilitate research

    • Personalized (Precision) Medicine: NGS of a patient’s cancer can be used to establish prognosis and predict susceptibilities to targeted therapies

  • Bioinformatics, Computing & Systems Biology to analyze big data sets

    • Helps identify new therapeutic targets and predict therapueitc resistance mechanisms



21
New cards

Biomarkers and types - what can they be used for

  • a biological molecule found in blood, other body fluids, or tissues that is a sign of a normal or abnormal process, or of a condition or disease

  • Can be proteins (normal, mutant, fusion), peptides, DNA, RNA, lipids

  • key to personalized medicine

  • can help identify heterogeneity and detect rare subpopulations

  • NGS, Massspec, NMR, and elisa and the ability to analyze the datasets they generate using Bioinformatics makes it easier to identify Biomarkers